INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 211 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2021. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $260,450 | -17.7% | 5,000 | 0.0% | 0.05% | -15.5% |
| Q2 2023 | $316,600 | +16.9% | 5,000 | 0.0% | 0.06% | +7.4% |
| Q1 2023 | $270,750 | +2.3% | 5,000 | 0.0% | 0.05% | -3.6% |
| Q4 2022 | $264,600 | -7.2% | 5,000 | 0.0% | 0.06% | -9.7% |
| Q2 2022 | $285,000 | -6.9% | 5,000 | 0.0% | 0.06% | -6.1% |
| Q1 2022 | $306,000 | -54.6% | 5,000 | -61.1% | 0.07% | -53.5% |
| Q4 2021 | $674,000 | +230.4% | 12,870 | +157.4% | 0.14% | +178.4% |
| Q2 2021 | $204,000 | -99.1% | 5,000 | -99.4% | 0.05% | -99.2% |
| Q2 2020 | $22,617,000 | +67.0% | 881,056 | 0.0% | 6.77% | +32.4% |
| Q1 2020 | $13,542,000 | – | 881,056 | – | 5.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 640,000 | $25,626,000 | 6.33% |
| Redmile Group, LLC | 1,322,592 | $52,957,000 | 4.01% |
| SENZAR ASSET MANAGEMENT, LLC | 556,224 | $22,271,209,000 | 3.24% |
| RA Capital Management | 314,349 | $12,587,000 | 1.81% |
| WALL STREET ASSOCIATES | 205,657 | $8,235,000 | 1.58% |
| Parametrica Management Ltd | 5,400 | $216,000 | 1.36% |
| Rhenman & Partners Asset Management AB | 165,000 | $6,607,000 | 1.05% |
| EAM Investors, LLC | 95,168 | $3,811,000 | 0.60% |
| Rock Springs Capital Management LP | 180,000 | $7,207,000 | 0.58% |
| WASATCH ADVISORS LP | 1,085,973 | $43,482,000 | 0.58% |